Spago Nanomedical's 177Lu-SN201 Shows Continued Safety in Phase I/IIa Trial Across Multiple Solid Tumors
核心洞察
Spago Nanomedical's independent Data Monitoring Committee recommends continuing the Tumorad-01 phase I/IIa study with 177Lu-SN201, allowing recruitment of two additional patients at the current dose level.
The recommendation follows analysis of 14 patients with advanced solid tumors (搜索), demonstrating acceptable safety profile with maximum tolerated dose not yet reached.
SPECT/CT imaging confirmed visible tumor uptake of 177Lu-SN201 in treated patients, providing proof-of-concept for the drug's mechanism of action in humans.
Spago Nanomedical AB announced that its independent Data Monitoring Committee (DMC) has recommended continuing the ongoing phase I/IIa Tumorad-01 study with drug candidate 177Lu-SN201, allowing parallel recruitment of two additional patients at the current dose level. The recommendation follows analysis of safety data from 14 patients with advanced cancer (搜索) across a broad spectrum of solid tumors (搜索), demonstrating a continued acceptable safety profile.
Safety Profile Supports Dose Escalation
The DMC's analysis of data from all 14 patients treated to date confirms the previously observed safety profile remains acceptable. Importantly, the committee concluded that the maximum tolerated dose (MTD) has not yet been reached, indicating potential for further dose escalation in the ongoing first-in-human study.
"The continued acceptable safety profile in patient groups with a broad range of solid tumors (搜索) is encouraging, and the DMC's recommendation to expand the current dose cohort with parallel recruitment of an additional two patients indicates further margin to MTD, providing important support for the continued clinical development of Tumorad," said CEO Mats Hansen.
Proof-of-Concept Demonstrated Through Imaging
Earlier in the study, SPECT/CT imaging revealed visible tumor uptake of 177Lu-SN201 in treated patients, which the company considers proof-of-concept for Tumorad in humans. This observation supports the drug's mechanism of action and indicates potential for therapeutic exposure using the clinically established isotope 177Lu.
Study Design and Regulatory Strategy
The phase I/IIa Tumorad-01 study is designed to evaluate the safety, tolerability, dosimetry, and initial efficacy of 177Lu-SN201 in adult patients with progressive or treatment-resistant advanced, unresectable, or metastatic solid tumors (搜索). The study is conducted sequentially with predefined evaluations performed by the DMC. The phase I portion aims to identify the MTD or recommended therapeutic dose for further evaluation in selected patient groups during the phase IIa portion.
Hansen noted that alongside determining the MTD and establishing dosing for phase II, the company's focus includes regulatory interactions aimed at defining the path forward for the program, including exploring potential orphan drug designation.
The study is registered at ClinicalTrials.gov under identifier NCT06184035. Spago Nanomedical's development projects are based on a platform of polymeric materials designed for more precise treatment and diagnosis of cancer and other debilitating diseases.